Lates News

According to AI Express, Pacific Securities released a research report on March 31, giving Taibao Biotechnology (688278.SH) a "buy" rating. The reasons for the rating mainly include: 1) The core product Pegasys: Hepatitis B clinical cure exclusive foundation, with vast growth space and strong certainty; 2) The second growth curve Yi Peisheng: Long-acting growth hormone medical insurance landing, opening a volume cycle; 3) The pipeline matrix is perfect, and the technical platform continues to empower long-term development: the company's blood tumor sector has formed a stable cash cow basic plate. (China Economic News)